ClinicalTrials.gg
CompletedNCT03934307Updated Jan 17, 2023

A Study to Evaluate ALN-AGT01 in Patients With Hypertension

A Phase 1 interventional study of ALN-AGT01 and ALN-AGT01-Matching Placebo in Hypertension, sponsored by Alnylam Pharmaceuticals. Completed at 3 sites in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-01-17.

Sponsored by Alnylam Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing irbesartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Irbesartan · Hypertension.

Enrollment
22nd of 41
124 · median 158
Started
2019
the only one that year
Phase 1
Only one
of the 41
Registered
40th of 41
by date
Lead sponsor
1 of 41
Alnylam Pharmaceuticals

Among the 41 studies testing irbesartan in Hypertension, this one is the 22nd largest by enrollment, is the only one that started in 2019, is the only one in phase 1, and was the 40th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 41 studies testing irbesartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About irbesartan

Irbesartan: first FDA approval 1997 (AVAPRO), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing irbesartan in Hypertension, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of subcutaneous (SC) ALN-AGT01 (zilebesiran) in participants with hypertension. The study will be conducted in 4 parts: Part A will be a single ascending dose (SAD) phase in hypertensive participants, Part B will be a single dose (SD) phase in hypertensive participants with controlled salt intake, Part D will be a MD phase in hypertensive participants who are obese, and Part E will be an open-label SD phase with co-administration of irbesartan in hypertensive patients.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has mild to moderate hypertension with mean sitting systolic blood pressure (SBP) of >130 and ≤165 mmHg without hypertensive medication for Parts A, B and D, and >135 and ≤165 mmHg without hypertensive medication for Part E
  • Parts A and B: Has (BMI) ≥18 and ≤35 kg/m\^2; Part D: Has BMI >35 and ≤50 kg/m\^2; Part E: Has BMI ≥18 kg/m\^2 and ≤50 kg/m\^2
  • Has a normal 12-lead (ECG)
  • Is a nonsmoker

Exclusion criteria

Exclusion Criteria:

  • Has secondary hypertension
  • Has orthostatic hypotension
  • Has estimated (eGFR) of \<60 mL/min/1.73m\^2
  • Recently received an agent
  • Has diabetes mellitus
  • Has history of any cardiovascular event
  • Has history of intolerance to SC injection(s)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    Part A: SAD: ALN-AGT01

    Participants will be administered a single dose of ALN-AGT01.

    Drug: ALN-AGT01

  • Placebo comparator
    Part A: SAD: ALN-AGT01-Matching Placebo

    Participants will be administered a single dose of ALN-AGT01-matching placebo.

    Drug: ALN-AGT01-Matching Placebo

  • Experimental
    Part B: SD: ALN-AGT01

    Participants with controlled salt intake will be administered a single dose of ALN-AGT01.

    Drug: ALN-AGT01

  • Placebo comparator
    Part B: SD: ALN-AGT01-Matching Placebo

    Participants with controlled salt intake will be administered a single dose of ALN-AGT01-matching placebo.

    Drug: ALN-AGT01-Matching Placebo

  • Experimental
    Part D: MD: ALN-AGT01 + Irbesartan-Matching Placebo

    Participants, who are obese, will be administered multiple doses of ALN-AGT01 and irbesartan-matching placebo.

    Drug: ALN-AGT01 · Drug: Irbesartan-Matching Placebo

  • Active comparator
    Part D: MD: ALN-AGT01-Matching Placebo + Irbesartan

    Participants, who are obese, will be administered multiple doses of ALN-AGT01-matching placebo and irbesartan.

    Drug: ALN-AGT01-Matching Placebo · Drug: Irbesartan

  • Experimental
    Part E: Open Label: ALN-AGT01 + Irbesartan

    Participants will be administered a single dose of ALN-AGT01 and multiple doses of irbesartan.

    Drug: ALN-AGT01 · Drug: Irbesartan

Interventions

  • ALN-AGT01 will be administered by subcutaneous (SC) injection.

    Also known as: Zilebesiran

  • DrugALN-AGT01-Matching Placebo

    Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC.

  • Irbesartan will be administered orally.

  • DrugIrbesartan-Matching Placebo

    Irbesartan-matching placebo will be administered orally.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    Time frame: Parts A, B and E: each up to approximately 12 months; Part D: up to approximately 18 months

Secondary outcomes

  1. Change from Baseline in Blood Angiotensinogen (AGT) Level

    Time frame: Parts A, B and E: each up to approximately 12 months; Part D: up to approximately 18 months

  2. Maximum Observed Plasma Concentration (Cmax) of ALN-AGT01 and of Potential Metabolites

    Time frame: Parts A, B and E: Up to Day 15; Part D: Up to Day 99

  3. Area Under the Concentration-time Curve (AUC) of ALN-AGT01 and of Potential Metabolites

    Time frame: Parts A, B and E: Up to Day 15; Part D: Up to Day 99

07

Study locations

3 sites
  • Clinical Trial Site
    Edinburgh, United Kingdom
  • Clinical Trial Site
    London, United Kingdom
  • Clinical Trial Site
    Manchester, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Apr 2022, 35 months.

Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 35 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2019
First posted
May 1, 2019
StartActual
May 1, 2019
Primary completionActual
Apr 20, 2022
CompletionActual
Jan 4, 2023
Last update
Jan 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03934307
Responsible party
Sponsor
First posted
May 1, 2019
Start date
May 1, 2019
Primary completion
Apr 20, 2022
Completion
Jan 4, 2023
Last update
Jan 17, 2023

Study contacts

Medical Director
study director · Alnylam Pharmaceuticals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zilebesiran · Irbesartan

Start the discussion